Chang R, Cannon R O, Chen C C, Doppman J L, Shawker T H, Mayo D J, Wood B, Horne M K
Department of Diagnostic Radiology, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Vasc Interv Radiol. 2001 Feb;12(2):247-52. doi: 10.1016/s1051-0443(07)61832-6.
The strong fibrin affinity of recombinant tissue plasminogen activator (rt-PA) theoretically obviates continuous infusion or replacement of t-PA after direct intrathrombic injection. This hypothesis led the authors to evaluate single daily catheter-directed injection of rt-PA as a thrombolytic treatment for acute deep vein thrombosis of the lower extremity. Once-daily injection of rt-PA was performed in large thrombosed veins (popliteal or larger) with use of pulse-spray catheters and in small thrombosed veins in patients' calves with use of 3-4-F coaxial catheters. Patients received only full systemic anticoagulation on his/her patient care unit. This dosing regimen has been tested in 10 patients (12 legs) with a maximum dose of 50 mg per leg per day. Extensive thrombolysis was achieved in nine patients and partial thrombolysis was achieved in one patient, at an average total dose of 106 mg of rt-PA per leg. Minor bleeding was seen in three patients and no transfusions were needed. Our technique and the rationale for this pilot study is the focus of this article.
重组组织型纤溶酶原激活剂(rt-PA)对纤维蛋白具有很强的亲和力,从理论上讲,在直接血栓内注射后无需持续输注或补充t-PA。这一假设促使作者评估每日单次导管定向注射rt-PA作为下肢急性深静脉血栓形成的溶栓治疗方法。使用脉冲喷射导管对大的血栓形成静脉(腘静脉或更大的静脉)以及使用3-4F同轴导管对患者小腿的小血栓形成静脉进行rt-PA每日一次注射。患者仅在其病房接受充分的全身抗凝治疗。该给药方案已在10例患者(12条腿)中进行了测试,每条腿每天的最大剂量为50 mg。9例患者实现了广泛溶栓,1例患者实现了部分溶栓,每条腿rt-PA的平均总剂量为106 mg。3例患者出现轻微出血,无需输血。本文重点介绍我们的技术以及这项初步研究的基本原理。